Skip to main content

BHVN Competitors

profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

Biohaven Pharmaceutical Holding Company Ltd. News

Cramer's Mad Money Recap 5/10: Upstart, Crocs, Biohaven Pharmaceuticals

Jim Cramer says that when the facts change, investors need to change their strategies.

Khloé Kardashian-Endorsed Migraine Drugmaker Biohaven Sold To Pfizer For $11.6 Billion

"We are excited to announce Pfizer’s proposed acquisition of Biohaven, recognizing the market leadership of Nurtec, our breakthrough all in one migraine therapy," said CEO Vlad Coric.

Cramer's Mad Money Recap 11/10: Rivian, Tesla, Amazon

Jim Cramer says there are many investors who believe Rivian will become the next Tesla and they're willing to buy in at any price.

Cramer's Mad Money Recap 11/8: Nucor, Advanced Micro Devices, Nvidia

Jim Cramer says that sometimes, good news for a stock also can be good news for investors.

Cramer's Mad Money Recap: J&J, Netflix, Nvidia, Tesla

Cramer says the clouds over Wall Street may have broken. Get ready for next week's earnings parade.

Breaking News

Micron Stock Tumbles On Grim Chip Sector Outlook After Q3 Earnings Beat

"We saw a significant reduction in near-term industry bit demand, primarily attributable to end demand weakness in consumer markets," said CEO Sanjay Mehrotra.

Tesla Q2 Deliveries In Focus Following Record Quarterly Stock Slump, China Shutdowns

Tesla will publish Q2 deliveries over the coming days following the biggest three-month decline on record for shares of the world's most-valuable carmaker.

Kohl's Stock Plunges As Retailer Scraps Franchise Group Sale Talks

"Given the environment and market volatility, the Board determined that it simply was not prudent to continue pursuing a deal," said chairman Peter Boneparth.

General Motors Stock Halted, Edge Higher After Detailing Q2 Chip Shortage Hit To Inventory

GM said chip shortages and supply chain snarls left nearly 100,000 vehicles unfinished over the second quarter.